Effect of L-DOPA and the catechol-O-methyltransferase inhibitor Ro 41- 0960 on sulfur amino acid metabolites in rats

Clinical Neuropharmacology

Volumn 20, Issue 1, 1997, Pages 55-66

  Miller, Joshua W ^a,b   Shukitt Hale, Barbara ^a   Villalobos Molina, Rafael ^a   Nadeau, Marie R ^a   Selhub, Jacob ^a   Joseph, James A ^a  

^a TUFTS UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Homocysteine; L Dopa; O Methylation; Parkinson's disease; Ro 41 0960; S Adenosylhomocysteine; S Adenosylmethionine

Indexed keywords

2' FLUORO 3,4 DIHYDROXY 5 NITROBENZOPHENONE; CATECHOL METHYLTRANSFERASE INHIBITOR; HOMOCYSTEINE; LEVODOPA; S ADENOSYLHOMOCYSTEINE; S ADENOSYLMETHIONINE; SULFUR AMINO ACID;

AMINO ACID METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE METABOLISM; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG INHIBITION; DRUG LIVER LEVEL; DRUG METABOLISM; DRUG TISSUE LEVEL; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; METHYLATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; VASCULAR DISEASE;

EID: 0031018201     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199702000-00007     Document Type: Article

References (52)

1. Calne DB. Treatment of Parkinson's disease. N Engl J Med 1993;329:1021-7.
2. Männistö PT, Ulmanen I, Lundström K, et al. Characteristics of catechol O-methyltransferase (COMT) and properties of selective COMT inhibitors. Prog Drug Res 1992;39:291-350.
3. Wurtman RJ. Effect of L-Dopa on S-adenosylmethionine levels and norepinephine metabolism in rat brain. In: Costa E, Iversen LL, Paoletti R, eds. Advances in biochemical psychopharmacology, vol 6. New York: Raven Pess, 1972:241-6.
4. Sharpless NS, Muenter MD, Tyce GM, Owen CA. 3- Methoxy-4-hydroxyphenylalanine (3-O-methyldopa) in plasma during oral L-Dopa therapy of patients with Parkinson's disease. Clin Chim Acta 1972;37:359-69.
5. Da Prada M, Keller HH, Pieri L, Kettler R, Haefely WE. The pharmacology of Parkinson's disease: basic aspects and recent advances. Experientia 1984;40:1165-72.
6. Kuruma I, Bartholini G, Tissot R, Pletscher A. Comparative investigaion of extracerebral dopa decarboxylase in man and rats. J Pharm Pharmacol 1972;24:289-94.
7. Messiha FS, Hsui TH, Bianchine JR. Peripheral aromatic L-amino acids decarboxylase inhibitor in parkinsonisim. J Clin Invest 1972;51:452-5.
8. Nutt JG, Fellman JH. Pharmacokinetics of levodopa. Clin Neuopharmacol 1984;7:35-49
9. Calne DB, Reid JL, Vakil SD. Pakinsonism treated with 3-O-methldopa. Clin Pharmacol Ther 1973;14:386-9.
10. Muenter MD, Dinapoli RP, Sharpless NS, Tyce GM. 3-O-Methyldopa, L-Dopa, and trihexyphenidyl in the treatmenl of Parkinson's disease. Mayo Clin Proc 1973;48:173-83.
11. Sharpless NS, Tyce NG, Muenter MD, Dinapoli RP. Dopa, 3-O-methyldopa, and metabolites in urine during oral L-3-0-methyldopa therapy. Clin Pharmacol Ther 1974;16:770-81.
12. Chalmers JP, Baldessarini RJ, Wurtman RJ. Effects of L-Dopa on norepinephrine metabolism in the brain. Proc Natl Acad Sci USA 1971;68:662-6.
13. Ordonez LA, Wurtman RJ. Methylation of exogenous 3,4-dihydroxyphenylalanine (L-Dopa) - effects on methyl group metabolism. Biochem Pharmacol 1973;22:134-7.
14. Ordonez LA, Wurtman RJ. Folic acid deficiency and methyl group metabolism in rat brain: effects of L-Dopa. Arch Biochem Biophs 1974;160:372-6.
15. Baldessarini RJ. Biological transmethylation involving S-adenosylmethionine: development of assay methods and implications for neuropschiatry. In: Pfeiffer CC, Smythies JR, eds. International review of neurobiology, New York: Academic Press. 1975:41-67.
16. Taylor KM, Randall PK. Depletion of S-adenosyl-L-methionine in mouse brain by antidepressive drugs. J Phamacol Exp Ther 1975;194:303-10.
17. Fuller RW, Hemrick-Luecke SK, Perry KW. Effects of L-Dopa on epinephrine concentration in rat brain: possible role of inhibition of norepinephrine N-methyltransferase by S-adenosylhomocysteine. J Phamacol Exp Ther 1982;223:84-9.
18. Fuller RW, Perry KW, Hemrick-Luecke SK. Tropolone antagonism of the L-Dopa-induced elevation of S-adenosylhomocystein: s-adenosylmethionine but not depletion of adrenaline in rat hypothalamus . J Pharm Pharmacol 1984;36:419-20.
19. Wagner J, Danzin C, Huot-Oliver S, Claverie N, Palfreyman MG. High-peformance liquid chromatographic analysis of S-adenosylmethoninie and its metabolites in rat tissues: interrelationship with changes in biogenic catechol levels following treatment with L- Dopa. J Chromatogr 1984;290:247-62.
20. Taufek HR, Bone AH. Influence of exogenous L-3,4-dihydroxyphenylalanine (L-Dopa) on the methionine and S-adenosylmethionine concentrations in the brain and other tissues. Biochem Soc Trans 1984;8:62-3.
21. Daly D, Miller JW, Nadeau MR, Selhub J. The effect of acute L-dopa administration on plasma homocys- teine levels, in folate replete and deplete rats [abstract]. FASEB Journal 1994;8:A920.
22. Matthysse S, Lipinski J, Shih V. L-Dopa and S-adenosylmethionine. Clin Chim 1971;35:253-4.
23. Surtees R, Hyland K. L-3,4-Dihydroxyphenyalanine (levodopa) lowers central nervous system S-adenosylmethionine concentrations in humans . J Neurol Neurosurg Psychiatry 1990;53:569-72.
24. Romero JA, Chalmers JP, Cottman K, Lytle LD, Wurtman RJ. Regional effects of L-dihydroxyphenyl alanine (L-Dopa) on norepinephrine metabolism in rat brain . J Pharmacol Exp Ther 1972;180:277-85.
25. Deguchi T, Barchas J. Inhibition ot transmethylations of biogenic amines by S-adenosylhomocysteine. J Biol Chem 1971;246:3175-81.
26. Coward JK, D' Urso-Scott, Sweet WD. Inhibition of catechol-O-methyltransferase by S-adenosyl homocysteine and S-adenosylhomocysteine sulfoxide, a potential transition-state analog. Biochem Pharmacol 1972;21:1200-3.
27. Baudry M, Chast F, Schwatz JC. studies on S-adenosylhomocysteine inhibition of histamine transmeth- ylation in brain. J neurochem 1973;20:13-21.
28. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia an independent risk factor for vascular disease. N Engl J Med 1991;324:1149-55.
29. Guldberg HC, Marsden CA. Catechol-O-methyltransferase pharmacological aspects and physiological role. Pharmacol Rev 1975;27:135-206.
30. Männistö PT, Kaakola S. New selective COMT inhibitors: useful adjuncts for Parkinson's disease? Trends Pharmacol Sci 1989;10:54-6.
31. Waldmeier PC, Baumann PA, Feldtrauer J-J, et al. CGP 28014, a new inhibitor of cerebal catechol-O- methylation with a non-catechol structure. Naunyn Schmiedebegs Arch Phamacol 1990;342:305-11.
32. Zürcher G, Dingemanse J, Da Prada M. Potent COMT inhibiton by Ro 40-7592 in the periphery and in the brain: preclinical and clinical findings. In: Narabayashi H, Nagatsu T, Yanagisawa N, Mizuno Y, eds. Advances in neurology, vol 60. New York : Raven Press, 1993:641-7.
33. Da Prada M, Borgulya J, Napolitano A, Zürcher G. Improved therapy of Parkinson's disease with tolcapone, a central and peripheral COMT inhibitor with an S-adenosyl-L-methionine-sparing effect. Clin Neuropharmacol 1994;17(suppl 3):S26-37.
34. Borgulya J, Buderer H, Bernauer K, Zürcher G, Da Prada M. Catechol-O-methyltransferase-inhibiting pyrocatechol deivatives : synthesis and structure-activity studies. Helv Chir Acta 1989;72:952-68.
35. Törnwall M, Männistö PT. Acute toxicity of three new selective COMT inhibitors in mice with special emphasis on interactions with drugs increasing catecholaminergic neurotransmission. Phamacol Toxicol 1991;69:64-70.
36. Männistö PT. Tuomainen P. Effect of high single doses of levopoda and carbidopa on brain dopamaine and its metabolites: modulation by selective inhibitors of monoamine oxidase and/or catechol-O-methyltransferase in the male rat. Naunyn Schmiedebergs Arch Phamacol 1991;344:412-8.
37. Törnwall M, Tuomainen P, Männistö PT. Neurochemieal and psychomotor interaction of new selective COMT inhibitors with clorgyline and nomifensive in levodopa-treated rats and mice. Arch Int Pharmacodyn Ther 1992;320:5-20.
38. Poirier LJ, Singh P, Sourkes TL. Boucher R. Effect of amine precursors on the concentration of striatal dopamine and serotonin in cats with and without unilateral brain stem lesions. Brain Res 1967;6:654-66.
39. Constantinidis J, Bartholini G, Tissot R, Pletscher A. Accumalation of dopamine in the parenchyma after decarboxylase inhibition in the capillaries of brain. Expeientia 1968;24:130-1.
40. Araki A, Sako Y. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr 1987;422:43-52.
41. Zürcher G, Keller HH, Kettler R, et al. Ro 40-7592, a novel, very potent, and orally active inhibitor of catechol-O-methyltransferase: a pharmacological study in rats In: Streifler MB, Korczyn AD, Melamed E. Youdmi MBH, eds. Advances in neurology, vol 53. New York: Raven Press, 1990:497-503.
42. Fell D, Benjamin LE, Steele RD. Determination of adenosine and S-adenosyl derivatives of sulfur amino acids in rat liver by high-perfomance liquid chromatography. J Chromatogr 1985;345:150-6.
43. Miller JW, Nadeau MR, Smith D, Selhub J. Vitamin B6 deficiency vs folate deficiency: comparison of responses to methionine loading in rats. Am J Clin Nutr 1994;59:1033-9.
44. Daniel WW. Biostatistics: a foundation for analysis in the health sciences. In: Barnett V, Bradley RA, Hunter JS, eds. Wiley series in probability and mathematical statitics. 4th ed. New York: Wiley, 1987;207-66.
45. Yu PH. Radioenzymatic estimation of S-adenosylmethionine in rat brain regions and subcellular fractions. Anal Biochem 1978;86:498-504.
46. Gharib A, Sarda N, Chabannes B,Cronenberger L, Pacheco H. The regional concentrations of S-adenosylmethionine. S-adenosyl-L-homocysteine, and adenosine in rat brain. J Neurochem 1982;38:810-5.
47. Sarda N, Reynaud D, Gharib A. S-adenosylmethionine, S-adenosylhomocysteine and adenosine system: age-dependent availability in rat brain. Dev Phamacol Ther 1989;13:104-12.
48. Waldmeier PC, Feldtrauer JJ. On the role of O-methylation in the metabolism of S-adenosylmethionine in rat brain. Biochem Pharmacol 1987;36:2855-61.
49. Beal MF, Fink JS, Martin JB. Parkinson's disease and other extrapyramidal disorders. In: Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL, eds. Harrison's pinciples of internal medicene. 13th ed. New York: McGraw-Hill. 1994:2275-80.
50. Baldessarini RJ. Neuropharmacology of S-adenosyl-L-methionine. Am J Med 1987;83(suppl 5A):95-103.
51. Carney MWP. Neuropharmacology of S-adenosyl methionine. Clin Neuropharmacol 1986;9:235-43.
52. Janicak PG, Lipinski J, Davis JM, et al. S-Adenosylmethionine in depression: a literature review and preliminary report. Ala J Med Sci 1988;25:306-13.